{
    "title": "113_s865",
    "content": "The \"Accelerating the End of Breast Cancer Act of 2013\" establishes a commission with specific duties, powers, and membership. It also includes provisions for coordination, evaluation, funding authorization, and termination. The Act begins with a short title and table of contents, followed by findings. The findings by Congress highlight the increasing prevalence of breast cancer, with 1 in 8 women in the US at risk. Globally, breast cancer is the most common cancer in women, leading to over 438,000 deaths in 2010. Metastasis is the main cause of death, accounting for over 90% of cases. The cost of breast cancer care in the US was $16.5 billion in 2010, with a significant impact on productivity. Advances in breast cancer research aim to improve understanding and prevention of cancer spread. Experts emphasize the need for interdisciplinary collaboration to address the complexity of the disease. Establishment of the Commission to Accelerate the End of Breast Cancer (referred to as the \"Commission\") with the purpose and duties outlined. The Commission's purpose is to end breast cancer by 2020. It will identify and promote initiatives to prevent breast cancer and metastasis, prioritizing those not addressed by the public or private sectors. Within 6 months of its establishment, the Commission will submit a strategic plan to the President. The Commission will submit an annual report to the President, Congress, and the public, describing its activities and financial expenditures for the preceding year. SEC. 5. MEMBERSHIP. The Commission shall consist of up to 10 members appointed by the President with Senate approval within 60 days of the Act's enactment. Members will represent varied disciplines in biomedical research, relevant disciplines outside of biomedical research, and patient advocates. The Commission consists of up to 10 members appointed by the President with Senate approval. Members represent varied disciplines in biomedical research, relevant disciplines outside of biomedical research, patient advocates, and categories related to breast cancer. Members are trained and prepared to participate in decision-making processes in science and medicine. The Commission consists of up to 10 members appointed by the President with Senate approval, representing varied disciplines in biomedical research, relevant disciplines outside of biomedical research, patient advocates, and categories related to breast cancer. Each member serves a 3-year term, can be reappointed, and vacancies are filled for the remainder of the term. A quorum of three members is required for the Commission to conduct business. The Commission consists of up to 10 members appointed by the President with Senate approval, representing varied disciplines in biomedical research, relevant disciplines outside of biomedical research, patient advocates, and categories related to breast cancer. Each member serves a 3-year term, can be reappointed, and vacancies are filled for the remainder of the term. A quorum of three members is required for the Commission to conduct business. SEC. 6. POWERS. The Commission has powers to hold hearings, request federal employees for assistance, and receive technical assistance from Federal agencies. The Commission may use the United States mails and obtain information from Federal agencies to carry out its duties. The Administrator of General Services shall provide administrative support services upon request. SEC. 7. CHAIRPERSON; PROGRAM MANAGERS. The Chairperson of the Commission appointed by the President has responsibilities including approving areas of study, developing assessment criteria, overseeing progress, and terminating studies not meeting the purpose. The Chairperson of the Commission may designate members as program managers to oversee areas of study and appoint staff to aid in achieving the purpose described in section 4(a). Program managers are responsible for recommending proposals and projects based on scientific merit. To achieve the purpose of preventing breast cancer and its metastasis, program directors may convene workshops, consult with experts, identify study areas, leverage resources, and perform other approved functions. They will also collaborate with federal agencies. 4(a). Collaborating with relevant Federal agencies to identify areas of mutual interest to maximize investment and promote joint projects. Monitoring study progress and recommending restructuring or termination as needed. SEC. 8. COORDINATION AND NONDUPLICATION. The Commission will coordinate its activities with other government programs and labs to avoid duplication. SEC. 9. EVALUATION OF THE COMMISSION. SEC. 9. EVALUATION OF THE COMMISSION. The President will have the Institute of Medicine evaluate the Commission's progress after 3 years, recommending whether it should continue or end, and sharing lessons learned. Authorization of funding for the Commission includes $8,000,000 for fiscal year 2013, $12,000,000 for each of fiscal years 2014 and 2015, and necessary sums for subsequent years until termination on June 1, 2020. No funds can be used for laboratory or pilot plant operations or construction."
}